methylphenidate has been researched along with Hyperactivity, Motor in 326 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures." | 7.80 | Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation. ( Asanuma, M; Kawakami, N; Liu, S; Mashimo, T; Matsui, H; Michiue, H; Miyazaki, I; Ohmori, I; Ouchida, M; Wang, H, 2014) |
| " It has been known to have side effects such as dyskinesia, but this case details the emergence of dystonia and dyskinesia when the simultaneous use of methylphenidate and a phenothiazine was followed by withdrawal of the phenothiazine." | 7.66 | Methylphenidate, neuroleptics and dyskinesia-dystonia. ( Chapel, J; Husain, A; Malek-Ahmadi, P, 1980) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 7.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| "Maternal smoking during pregnancy, a form of developmental nicotine exposure (DNE), is associated with increased nicotine use and neurodevelopmental disorders such as ADHD in children." | 3.91 | Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice. ( Buck, JM; Knopik, VS; O'Neill, HC; Sanders, KN; Stitzel, JA; Wageman, CR, 2019) |
| " Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures." | 3.80 | Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation. ( Asanuma, M; Kawakami, N; Liu, S; Mashimo, T; Matsui, H; Michiue, H; Miyazaki, I; Ohmori, I; Ouchida, M; Wang, H, 2014) |
| " It has been known to have side effects such as dyskinesia, but this case details the emergence of dystonia and dyskinesia when the simultaneous use of methylphenidate and a phenothiazine was followed by withdrawal of the phenothiazine." | 3.66 | Methylphenidate, neuroleptics and dyskinesia-dystonia. ( Chapel, J; Husain, A; Malek-Ahmadi, P, 1980) |
| "In a child with minimal brain dysfunction, we found that chorea was related to the major central effect of methylphenidate and probably to the effect of the drug on central catecholaminergic systems." | 3.66 | Methylphenidate-induced chorea: case report and pharmacologic implications. ( Klawans, HL; Nausieda, PA; Weiner, WJ, 1978) |
| "Although the FDA recommends imipramine hydrochloride (IMI) only for temporary relief of symptoms of enuresis nocturna (EN), the drug has been applied to a number of other pediatric situations, including the Hyperkinetic Syndrome (HS), childhood depression, somnambulism and pavor nocturnus, school phobia, petit mal epilepsy, allergies, autism, encorpresis and head-banging." | 3.65 | Imipramine and children: a review and some speculations about the mechanism of drug action. ( Gualtieri, CT, 1977) |
| " Teacher rating data showed equivalent effects of therapy and the low dosage of methylphenidate alone but a stronger effect of the high dose alone; only the high dose resulted in improved behavior after 13 weeks of behavioral intervention." | 2.65 | Behavioral and stimulant treatment of hyperactive children: a therapy study with methylphenidate probes in a within-subject design. ( Bologna, NC; Contreras, JA; Pelham, WE; Schnedler, RW, 1980) |
| "Chlorpromazine was effective for the majority of the children, but reduced only hyperactivity, having no demonstrable effect on distractibility, aggressivity or excitability." | 2.64 | Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children. ( Douglas, V; Minde, K; Sykes, D; Weiss, G; Werry, J, 1971) |
| " Methylphenidate dosage was individualized." | 2.64 | Relative efficacy of methylphenidate and behavior modification in hyperkinetic children: an interim report. ( Abikoff, H; Gittelman-Klein, R; Gloisten, AC; Kates, W; Katz, S; Klein, DF, 1976) |
| "Methylphenidate was found to reduce hyperactivity at home, but it did not improve nursery behavior or psychological functioning." | 2.64 | Hyperactivity in preschoolers and the effect of methylphenidate. ( Cohen, N; Cvejic, H; Elman, M; Kruger, E; Schleifer, M; Weiss, G, 1975) |
| " A wide range of dosage (0." | 2.64 | Observations on effects of a central stimulant drug (methylphenidate) in children with hyperactive behavior. ( Reynard, CL; Schain, RJ, 1975) |
| "Further research of degree of hyperkinesis, age-level, sensory modality and drug administration was suggested." | 2.64 | The effect of methylphenidate on sensory perception in varying degrees of hyperkinetic behaviour. ( Butter, HJ; Lapierre, YD, 1975) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "Methylphenidate-treated children showed significant weight loss but no significant changes in blood pressure or pulse." | 2.64 | Blood pressure and pulse changes in hyperactive children treated with imipramine and methylphenidate. ( Greenberg, LM; Yellin, AM, 1975) |
| " These results had been hypothesized from theoretical dose-response curves which indicate different target behaviors would improve at different doses." | 2.64 | Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. ( Sleator, EK; Sprague, RL, 1977) |
| "To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate." | 2.48 | How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. ( Granger, RE; Hazell, PL; Kohn, MR; van Wyk, GW; Walton, RJ, 2012) |
| " After changing the dosage of methylphenidate and additionally using dog appeasing pheromone, the behavior of the bitch became normal after 8 days." | 1.40 | [Methylphenidate use in dogs with attention deficit hyperactivity disorder (ADHD). A case report of a Weimaraner bitch]. ( Piturru, P, 2014) |
| " Thus, the objective of the present study was to determine whether acute and chronic administration of MPD (0." | 1.33 | Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains. ( Dafny, N; Swann, AC; Yang, PB, 2006) |
| " Of the patients in whom the MPD therapy was effective, the majority received a MPD dosage of 0." | 1.31 | [Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia]. ( Ishizaki, A; Sugama, M, 2001) |
| " Pharmacokinetic parameters for children receiving 0." | 1.27 | Pharmacokinetics of methylphenidate in man, rat and monkey. ( Breese, GR; Ellington, K; Gualtieri, CT; Kilts, C; Kraemer, G; Mueller, RA; Patrick, K; Wargin, W, 1983) |
| " The augmenters were blindly titrated at significantly lower dosage levels than the reducers." | 1.27 | Auditory ERP augmentation-reduction and methylphenidate dosage needs in attention and reading disordered children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1983) |
| "When amphetamine therapy was combined systematically with conditioning experiments and psychosocial therapy, for long enough periods of time (many weeks), the beneficial effects of this drug persisted in the nodrug state, i." | 1.27 | Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis. ( Corson, EO; Corson, SA, 1988) |
| "Gilles de la Tourette syndrome is frequently associated with symptoms characteristic of hyperactivity and often goes unrecognized for long periods of time." | 1.26 | Deleterious effects of drugs used for hyperactivity on patients with Gilles de la Tourette syndrome. ( Sleator, EK, 1980) |
| " The combination of a clinically useful medication in appropriate dosage schedules with relevant psychological treatments simultaneously directed to each of the child's many disabilities were associated with an unexpectedly good outcome at the end of one and two years." | 1.26 | Multimodality treatment. A two-year evaluation of 61 hyperactive boys. ( Cantwell, DP; Satterfield, BT; Satterfield, JH, 1980) |
| "One hundred children with the hyperkinetic syndrome or minimal brain dysfunction syndrome were treated with medication: 60 with methylphenidate (Ritalin), 24 with dextroamphetamine (Dexedrine), and 16 with either imipramine or desipramine." | 1.26 | Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. ( Gross, MD, 1976) |
| " This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays." | 1.26 | The effects of stimulant medication on the growth of hyperkinetic children. ( Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979) |
| "1 Pharmacokinetic study has been carried out following oral administration of 10-20 mg of methylphenidate hydrochloride to four behaviorally disorders children." | 1.26 | Pharmacokinetics of methylphenidate in hyperkinetic children. ( Hungund, BL; Hurwic, MJ; Perel, JM; Sverd, J; Winsberg, BG, 1979) |
| "Gilles de la Tourette's syndrome was independently ascertained in two male cousins once removed." | 1.26 | Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. ( Cohen, NL; Friedhoff, AJ; Pollack, MA, 1977) |
| "Depression is an important cause of behavioral disturbances in children." | 1.26 | Childhood depression: an explanation of a behavior disorder of children. ( Brumback, RA; Weinberg, WA, 1977) |
| "Methylphenidate is a useful, proven method for the effective treatment of minimal brain dysfunction (MBD)." | 1.26 | Methylphenidate: a review. ( Majovski, LV; Oettinger, L, 1976) |
| " No clinical predictors of growth deficits were found; growth in height deficits are not related to total dosage or summer drug holidays, but weight deficits may be related to these factors." | 1.26 | Growth of hyperactive children treated with methylphenidate. ( Blaschke, T; Cantwell, DP; Satterfield, JH; Schell, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 292 (89.57) | 18.7374 |
| 1990's | 11 (3.37) | 18.2507 |
| 2000's | 7 (2.15) | 29.6817 |
| 2010's | 12 (3.68) | 24.3611 |
| 2020's | 4 (1.23) | 2.80 |
| Authors | Studies |
|---|---|
| Lages, YV | 1 |
| Maisonnette, SS | 1 |
| Rosseti, FP | 1 |
| Galvão, BO | 1 |
| Landeira-Fernandez, J | 1 |
| Jhang, CL | 1 |
| Lee, HY | 1 |
| Chen, JC | 1 |
| Liao, W | 1 |
| Asth, L | 1 |
| Tiago, PRF | 1 |
| Costa, LRF | 1 |
| Holanda, VAD | 1 |
| Pacifico, S | 1 |
| Zaveri, NT | 1 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Hori, T | 1 |
| Ikuta, S | 1 |
| Hattori, S | 1 |
| Takao, K | 1 |
| Miyakawa, T | 1 |
| Koike, C | 1 |
| Buck, JM | 1 |
| Sanders, KN | 1 |
| Wageman, CR | 1 |
| Knopik, VS | 1 |
| Stitzel, JA | 1 |
| O'Neill, HC | 1 |
| Piturru, P | 1 |
| Ohmori, I | 1 |
| Kawakami, N | 1 |
| Liu, S | 1 |
| Wang, H | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 1 |
| Michiue, H | 1 |
| Matsui, H | 1 |
| Mashimo, T | 1 |
| Ouchida, M | 1 |
| Urch, T | 1 |
| Pozzi, M | 1 |
| Bertella, S | 1 |
| Molteni, M | 1 |
| Antoniazzi, S | 1 |
| Carnovale, C | 1 |
| Gentili, M | 1 |
| Pellegrino, P | 1 |
| Perrone, V | 1 |
| Clementi, E | 1 |
| Radice, S | 1 |
| Ohashi, K | 1 |
| Vitaliano, G | 1 |
| Polcari, A | 1 |
| Teicher, MH | 1 |
| Krapacher, FA | 1 |
| Mlewski, EC | 1 |
| Ferreras, S | 1 |
| Pisano, V | 1 |
| Paolorossi, M | 1 |
| Hansen, C | 1 |
| Paglini, G | 1 |
| Griggs, R | 1 |
| Weir, C | 1 |
| Wayman, W | 1 |
| Koeltzow, TE | 1 |
| van Wyk, GW | 1 |
| Hazell, PL | 1 |
| Kohn, MR | 1 |
| Granger, RE | 1 |
| Walton, RJ | 1 |
| Niimi, K | 1 |
| Nishioka, C | 1 |
| Miyamoto, T | 1 |
| Takahashi, E | 1 |
| Miyoshi, I | 1 |
| Itakura, C | 1 |
| Yamashita, T | 1 |
| Green, T | 1 |
| Weinberger, R | 1 |
| Diamond, A | 1 |
| Berant, M | 1 |
| Hirschfeld, L | 1 |
| Frisch, A | 1 |
| Zarchi, O | 1 |
| Weizman, A | 1 |
| Gothelf, D | 1 |
| Mines, MA | 1 |
| Beurel, E | 1 |
| Jope, RS | 1 |
| Rhodes, JS | 1 |
| Garland, T | 1 |
| ALBANO, G | 1 |
| DIBENEDETTO, A | 1 |
| CRISCUOLI, PM | 1 |
| INDOVINA, T | 1 |
| CANDIA, A | 1 |
| CIULLA, C | 1 |
| Taylor, E | 2 |
| Döpfner, M | 1 |
| Sergeant, J | 1 |
| Asherson, P | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Rothenberger, A | 1 |
| Sonuga-Barke, E | 1 |
| Steinhausen, HC | 1 |
| Zuddas, A | 1 |
| Siesser, WB | 1 |
| Zhao, J | 1 |
| Miller, LR | 1 |
| Cheng, SY | 1 |
| McDonald, MP | 1 |
| Yang, PB | 1 |
| Swann, AC | 1 |
| Dafny, N | 1 |
| Müller Smith, K | 1 |
| Fagel, DM | 1 |
| Stevens, HE | 1 |
| Rabenstein, RL | 1 |
| Maragnoli, ME | 1 |
| Ohkubo, Y | 1 |
| Picciotto, MR | 1 |
| Schwartz, ML | 2 |
| Vaccarino, FM | 1 |
| Craggs, MD | 1 |
| Wright, JJ | 1 |
| Werry, JS | 8 |
| Martin, CA | 1 |
| Welsh, RJ | 1 |
| McKay, SE | 1 |
| Bareuther, CM | 1 |
| Wargin, W | 1 |
| Patrick, K | 2 |
| Kilts, C | 1 |
| Gualtieri, CT | 4 |
| Ellington, K | 1 |
| Mueller, RA | 1 |
| Kraemer, G | 1 |
| Breese, GR | 3 |
| Hicks, RE | 1 |
| Schroeder, SR | 2 |
| Dykman, RA | 1 |
| Holcomb, PJ | 1 |
| Ackerman, PT | 1 |
| McCray, DS | 1 |
| Schechter, MD | 1 |
| Concannon, JT | 1 |
| Dyme, IZ | 1 |
| Sahakian, BJ | 1 |
| Golinko, BE | 1 |
| Rabe, EF | 1 |
| Sleator, EK | 9 |
| Salzinger, K | 1 |
| Rapoport, JL | 7 |
| Nee, L | 1 |
| Mitchell, S | 1 |
| Polinsky, R | 1 |
| Ebert, M | 1 |
| Dickerson, JW | 1 |
| Pepler, F | 1 |
| Schultz, FR | 1 |
| Hayford, JT | 1 |
| Wolraich, ML | 3 |
| Hintz, RL | 1 |
| Thompson, RG | 1 |
| Chan, YM | 1 |
| Soldin, SJ | 1 |
| Swanson, JM | 5 |
| Deber, CM | 1 |
| Thiessen, JJ | 1 |
| Macleod, S | 1 |
| Loney, J | 6 |
| Whaley-Klahn, MA | 1 |
| Ponto, LB | 1 |
| Adney, K | 1 |
| Kanoy, R | 1 |
| Hawk, B | 1 |
| Koriath, U | 1 |
| Schroeder, S | 1 |
| Youngblood, W | 1 |
| Prange, AJ | 1 |
| Aman, MG | 5 |
| Diamond, E | 1 |
| Anderson, J | 1 |
| Harbauer, H | 1 |
| Minde, KK | 3 |
| Husain, A | 1 |
| Chapel, J | 1 |
| Malek-Ahmadi, P | 1 |
| Martinius, J | 1 |
| Whalen, CK | 5 |
| Henker, B | 5 |
| Dotemoto, S | 2 |
| Pelham, WE | 3 |
| Schnedler, RW | 1 |
| Bologna, NC | 1 |
| Contreras, JA | 1 |
| Kazdin, AE | 1 |
| Brown, RT | 3 |
| Greenhill, LL | 1 |
| Puig-Antich, J | 1 |
| Halpern, F | 1 |
| Sachar, EJ | 1 |
| Rubinstein, B | 1 |
| Chambers, W | 1 |
| Fiscina, B | 1 |
| Florea, J | 1 |
| Winsberg, BG | 6 |
| Hungund, BL | 2 |
| Perel, JM | 2 |
| Robertson, EJ | 1 |
| Klopper, JN | 2 |
| Robertson, LI | 1 |
| Logue, G | 1 |
| Martins, U | 1 |
| Satterfield, JH | 7 |
| Satterfield, BT | 3 |
| Cantwell, DP | 6 |
| Padan, J | 1 |
| Gunning, WB | 1 |
| Vatz, RE | 1 |
| Weinberg, LS | 1 |
| Baughman, FA | 1 |
| Mills, IH | 1 |
| Ogura, H | 1 |
| Furuya, Y | 1 |
| Teramoto, T | 1 |
| Niidome, T | 1 |
| Nishizawa, Y | 1 |
| Yamanishi, Y | 1 |
| Marx, J | 1 |
| Robison, LM | 1 |
| Sclar, DA | 1 |
| Skaer, TL | 1 |
| Galin, RS | 1 |
| Hill, P | 1 |
| Ishizaki, A | 1 |
| Sugama, M | 1 |
| Mills, C | 1 |
| O'Leary, JC | 1 |
| Lambert, NM | 2 |
| Windmiller, M | 1 |
| Sandoval, J | 2 |
| Moore, B | 1 |
| Bhatara, V | 1 |
| Arnold, LE | 4 |
| Knopp, W | 2 |
| Smeltzer, DJ | 2 |
| Simeon, J | 1 |
| O'Malley, M | 1 |
| Tryphonas, H | 1 |
| Graham, D | 1 |
| Mastronardi, M | 1 |
| Simeon, S | 1 |
| Griffin, J | 1 |
| Cole, SO | 2 |
| Hastings, JE | 1 |
| Barkley, RA | 9 |
| Silver, LB | 2 |
| Barker, D | 1 |
| Krager, JM | 3 |
| Safer, D | 3 |
| Earhart, J | 1 |
| Golden, GS | 2 |
| Pollack, MA | 1 |
| Cohen, NL | 1 |
| Friedhoff, AJ | 1 |
| Codd, JA | 1 |
| Bremness, AB | 1 |
| Sverd, J | 2 |
| Aarskog, D | 1 |
| Fevang, FO | 1 |
| Klove, H | 1 |
| Stoa, KF | 1 |
| Thorsen, T | 1 |
| Sells, CJ | 2 |
| Eaton, M | 1 |
| Lucas, B | 2 |
| Yepes, LE | 1 |
| Balka, EB | 2 |
| Bialer, I | 2 |
| Wulbert, M | 1 |
| Dries, R | 1 |
| McNutt, BA | 1 |
| Boileau, RA | 3 |
| Cohen, MN | 1 |
| Gittelman, R | 1 |
| Jackson, TL | 1 |
| Sprague, RL | 11 |
| Margolin, DI | 2 |
| Williams, JI | 1 |
| Cram, DM | 1 |
| Tausig, FT | 1 |
| Webster, E | 1 |
| Dalby, JT | 2 |
| Kapelus, GJ | 1 |
| Kinsbourne, M | 7 |
| Roberts, W | 1 |
| Christopher, J | 1 |
| Huestis, R | 1 |
| Cunningham, CE | 3 |
| Collins, BE | 3 |
| Authier, J | 1 |
| Donaldson, J | 1 |
| Prica, G | 1 |
| Alperin, E | 1 |
| Ensz, G | 1 |
| Schell, A | 1 |
| Blaschke, T | 1 |
| Langhorne, JE | 1 |
| Hiscock, M | 1 |
| Caplan, B | 1 |
| Leary, PM | 2 |
| Arens, L | 1 |
| Marshall, S | 1 |
| Schadle, S | 1 |
| AvRuskin, TW | 1 |
| Lala, V | 1 |
| Tang, SC | 1 |
| Juan, CS | 1 |
| Axelrod, S | 1 |
| Bailey, SL | 1 |
| Stahl, ML | 1 |
| Orr, WC | 1 |
| Griffiths, WJ | 1 |
| Houghton, RR | 1 |
| Tabachnick, BG | 1 |
| Roche, AF | 1 |
| Lipman, RS | 1 |
| Overall, JE | 1 |
| Hung, W | 1 |
| Levin, WJ | 1 |
| Goyer, PF | 1 |
| Davis, GC | 1 |
| Finck, D | 1 |
| Weissenburger, FE | 1 |
| Woolson, RF | 1 |
| Lichty, EC | 1 |
| Backman, J | 1 |
| Firestone, P | 2 |
| Gordon, NG | 1 |
| Kantor, DR | 1 |
| McAuliffe, S | 1 |
| Vaux, A | 1 |
| Ross, DC | 1 |
| Klein, DF | 4 |
| Charles, L | 2 |
| Schain, RJ | 4 |
| Zelniker, T | 1 |
| Guthrie, D | 2 |
| Coleman, M | 2 |
| Steinberg, G | 2 |
| Tippett, J | 2 |
| Bhagavan, HN | 1 |
| Coursin, DB | 1 |
| Gross, M | 1 |
| Lewis, C | 1 |
| DeVeau, L | 1 |
| Smith, TA | 1 |
| Kronick, RF | 1 |
| Thurston, CM | 1 |
| Sobol, MP | 2 |
| Swanson, J | 2 |
| Shouse, MN | 2 |
| Lubar, JF | 2 |
| Hurwic, MJ | 1 |
| Arens, LJ | 1 |
| Marshall, SR | 1 |
| Rabkin, J | 1 |
| Weiner, WJ | 1 |
| Nausieda, PA | 1 |
| Klawans, HL | 1 |
| Surwillo, WW | 1 |
| Humphries, T | 1 |
| Wolraich, M | 1 |
| Drummond, T | 1 |
| Salomon, MK | 1 |
| O'Brien, ML | 1 |
| Sivage, C | 1 |
| Barter, M | 1 |
| Kammer, H | 1 |
| O'Leary, SG | 1 |
| McManis, DI | 1 |
| McCarthy, M | 1 |
| Koval, R | 1 |
| Berger, M | 1 |
| Ober, ML | 1 |
| Braud, LW | 1 |
| Fahrmeier, ED | 1 |
| Ullman, DG | 1 |
| Brown, HW | 1 |
| Davey, J | 1 |
| Goodman, JT | 1 |
| Peters, S | 1 |
| Prinz, RJ | 1 |
| Mishalow, J | 1 |
| Joad, J | 1 |
| Millichap, JG | 6 |
| Klorman, R | 1 |
| Salzman, LF | 1 |
| Pass, HL | 1 |
| Borgstedt, AD | 1 |
| Dainer, KB | 1 |
| Morrison, TL | 1 |
| Thomas, MD | 1 |
| Lerer, RJ | 1 |
| Lerer, MP | 1 |
| Rie, HE | 2 |
| Rie, ED | 1 |
| Stewart, S | 1 |
| Ambuel, JP | 1 |
| Lampen, E | 1 |
| Spring, C | 4 |
| Yellin, AM | 3 |
| Greenberg, L | 3 |
| Ballard, JE | 2 |
| Massey, BH | 2 |
| Baxley, GB | 1 |
| LeBlanc, JM | 1 |
| Seals, JR | 1 |
| Weiss, G | 6 |
| Kruger, E | 3 |
| Danielson, U | 2 |
| Elman, M | 3 |
| Kupietz, SS | 3 |
| Nahas, AD | 1 |
| Krynicki, V | 1 |
| Shafto, F | 1 |
| Sulzbacher, S | 1 |
| White, JH | 2 |
| Conner, AE | 1 |
| Levine, EM | 1 |
| Kozak, C | 1 |
| Shaiova, CH | 1 |
| Renshaw, DC | 1 |
| Brumback, RA | 1 |
| Weinberg, WA | 1 |
| Greenberg, LM | 2 |
| Halpern, WI | 1 |
| Gross, MD | 3 |
| Gittelman-Klein, R | 3 |
| Katz, S | 2 |
| Saraf, K | 1 |
| Pollack, E | 1 |
| Prichep, LS | 1 |
| Sutton, S | 1 |
| Hakerem, G | 1 |
| Halliday, R | 1 |
| Rosenthal, JH | 1 |
| Naylor, H | 1 |
| Callaway, E | 1 |
| Greenberg, A | 1 |
| Bhagavan, H | 1 |
| Coursin, D | 1 |
| Abikoff, H | 1 |
| Gloisten, AC | 1 |
| Kates, W | 1 |
| Edwards, EM | 1 |
| Renshaw, D | 1 |
| Moore, SF | 1 |
| Anonsen, DC | 2 |
| Rapaport, HG | 1 |
| Flint, SH | 1 |
| Schleifer, M | 1 |
| Cohen, N | 1 |
| Cvejic, H | 1 |
| Quinn, PO | 4 |
| Allen, RP | 5 |
| Covi, L | 1 |
| Reynard, CL | 1 |
| Garfinkel, BD | 1 |
| Webster, CD | 1 |
| Sloman, L | 1 |
| Butter, HJ | 3 |
| Lapierre, YD | 3 |
| Palmer, S | 1 |
| Itil, TM | 1 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Christensen, DE | 2 |
| Springer, NS | 1 |
| Fricke, NL | 1 |
| Safer, DJ | 6 |
| Barr, E | 2 |
| Denson, R | 1 |
| Nanson, JL | 1 |
| McWatters, MA | 1 |
| Milberg, RM | 1 |
| Rinehart, KL | 1 |
| Logue, GD | 1 |
| Porges, SW | 1 |
| Walter, GF | 1 |
| Korb, RJ | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Ordoña, TT | 1 |
| Ayllon, T | 1 |
| Layman, D | 1 |
| Kandel, HJ | 1 |
| Sulzbacher, SI | 1 |
| Weithorn, CJ | 1 |
| Ross, R | 1 |
| Oettinger, L | 2 |
| Majovski, LV | 1 |
| Stableford, W | 1 |
| Butz, R | 1 |
| Leitenberg, H | 1 |
| Peyser, J | 1 |
| Yandell, W | 1 |
| Akins, K | 1 |
| Drtílková, I | 1 |
| Misurec, J | 1 |
| Náhunek, K | 1 |
| Borcherding, BG | 1 |
| Keysor, CS | 1 |
| Cooper, TB | 1 |
| Corson, SA | 1 |
| Corson, EO | 1 |
| Maitinsky, S | 2 |
| Richardson, E | 2 |
| Sexson, SB | 1 |
| Mendell, N | 1 |
| Solomons, G | 1 |
| Van Osdol, BM | 1 |
| Carlson, L | 1 |
| Carman, JS | 2 |
| Faigel, HC | 1 |
| Tucker, LS | 1 |
| Selye, H | 1 |
| Szabo, S | 1 |
| Mécs, I | 1 |
| Sroufe, LA | 1 |
| Stewart, MA | 1 |
| Sarma, PS | 1 |
| Falk, MA | 1 |
| Feighner, AC | 1 |
| Feighner, JP | 1 |
| Haig, JR | 1 |
| Schroeder, CS | 1 |
| Ney, PG | 1 |
| Chamberlain, RW | 1 |
| Robin, SS | 1 |
| Bosco, JJ | 1 |
| Eisenberg, L | 2 |
| Lesser, LI | 1 |
| Podosin, RL | 1 |
| DeLong, AR | 1 |
| Allen, R | 1 |
| Sykes, DH | 2 |
| Douglas, VI | 3 |
| Morgenstern, G | 2 |
| Wender, PH | 1 |
| Von Neumann, AW | 1 |
| Press, M | 1 |
| Kupietz, S | 1 |
| Bradbard, G | 1 |
| Riddle, KD | 1 |
| Brooks, E | 1 |
| Von Neumann, A | 1 |
| Rapoport, J | 1 |
| Quinn, P | 1 |
| Scribanu, N | 1 |
| Murphy, DL | 1 |
| Omenn, GS | 1 |
| Nissen, G | 1 |
| Alabiso, F | 1 |
| Watter, N | 1 |
| Dreifuss, FE | 1 |
| Scott, J | 2 |
| Hopwood, J | 1 |
| Green, RP | 1 |
| Scales, SM | 1 |
| Rosser, PL | 1 |
| Chapple, PA | 1 |
| Schnackenberg, RC | 1 |
| Machanick, S | 1 |
| Ullrich, JR | 1 |
| Reece, RM | 1 |
| Chapel, JL | 1 |
| Verret, S | 1 |
| O'Malley, JE | 1 |
| Hoffman, SP | 1 |
| Engelhardt, DM | 1 |
| Margolis, RA | 1 |
| Polizos, P | 1 |
| Waizer, J | 1 |
| Rosenfeld, R | 1 |
| Lamprecht, F | 1 |
| Morrison, JR | 1 |
| Wells, R | 1 |
| Hammond, KB | 1 |
| Rodgerson, DO | 1 |
| Ellis, MJ | 1 |
| Witt, PA | 1 |
| Reynolds, R | 1 |
| Peters, JE | 1 |
| Hopwood, H | 1 |
| Silbergeld, EK | 2 |
| Goldberg, AM | 2 |
| Barnes, KR | 1 |
| Greenwold, WE | 1 |
| Jones, PR | 1 |
| Cohen, NJ | 1 |
| Shetty, T | 2 |
| Barkai, A | 1 |
| Lingjaerde, O | 1 |
| Nichamin, SJ | 1 |
| Rothschild, CJ | 1 |
| Nicol, H | 1 |
| McCabe, ER | 1 |
| McCabe, L | 1 |
| Erenberg, G | 1 |
| Howell, MC | 1 |
| Rever, GW | 1 |
| Scholl, ML | 1 |
| Trowbridge, F | 1 |
| Rutledge, A | 1 |
| Dawson, ME | 1 |
| Pizzo, SV | 1 |
| McKee, PA | 1 |
| Turner, EJ | 1 |
| Cohn, HD | 1 |
| Tec, L | 2 |
| Levy, HB | 1 |
| Lucas, AR | 1 |
| Weiss, M | 1 |
| Conners, CK | 1 |
| Fischer, KC | 1 |
| Wilson, WP | 1 |
| Minde, K | 1 |
| Douglas, V | 1 |
| Werry, J | 1 |
| Sykes, D | 1 |
| Olsen, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder[NCT02477280] | Phase 4 | 39 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD[NCT02473185] | Phase 4 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials[NCT02695355] | Phase 2 | 87 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Methylphenidate Efficacy and Safety in ADHD Preschoolers[NCT00018863] | Phase 3 | 165 participants | Interventional | 2001-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
27 reviews available for methylphenidate and Hyperactivity, Motor
| Article | Year |
|---|---|
How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attentio | 2012 |
Hyperactivity (attention-deficit disorder).
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Family; Female; Humans; Hyp | 1984 |
Diet and hyperactivity.
Topics: Adolescent; Aging; Amphetamines; Child; Child Behavior Disorders; Child, Preschool; Diet; Dietary Ca | 1980 |
[Attention deficit disorder with hyperactivity].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child, Pr | 1994 |
National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dru | 1999 |
An auditable protocol for treating attention deficit/hyperactivity disorder.
Topics: Algorithms; Attention Deficit Disorder with Hyperactivity; Child; Clinical Protocols; Clinical Trial | 2001 |
Hyperactive children and the efficacy of psychoactive drugs as a treatment intervention.
Topics: Amphetamines; Central Nervous System Stimulants; Child Behavior; Chlordiazepoxide; Chlorpromazine; C | 1976 |
Hyperkinetic children: the use of stimulant drugs evaluated.
Topics: Achievement; Animals; Attention; Blood Pressure; Central Nervous System; Dextroamphetamine; Feeding | 1975 |
Acceptable and controversial approaches to treating the child with learning disabilities.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Attention; Child; | 1975 |
A review of stimulant drug research with hyperactive children.
Topics: Achievement; Amphetamines; Attention; Autonomic Nervous System; Body Height; Body Weight; Cerebral C | 1977 |
The hyperkinetic child syndrome and brain monoamines: pharmacology and therapeutic implications.
Topics: Animals; Arousal; Attention; Brain; Child; Dextroamphetamine; Disease Models, Animal; Dopamine; Huma | 1978 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
Psychostimulants and children: a review and analysis.
Topics: Attention; Child; Child Behavior; Cognition; Dextroamphetamine; Drug Evaluation; Humans; Hyperkinesi | 1976 |
The hyperactive child: characteristics, treatment, and evaluation of research design.
Topics: Central Nervous System Diseases; Child; Child Behavior; Dextroamphetamine; Electroencephalography; H | 1976 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
MBD: advanced in understanding many bothersome dilemmas.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool | 1976 |
Effects of psychostimulants on aggression.
Topics: Adolescent; Aggression; Amphetamine; Animals; Child; Dextroamphetamine; Dogs; Dose-Response Relation | 1975 |
Minimal brain Dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Cerebral Palsy; Child; Child, Prescho | 1975 |
Nutrition and drug therapy for persons with developmental disabilities.
Topics: Anticonvulsants; Antidepressive Agents; Appetite; Dextroamphetamine; Drug-Related Side Effects and A | 1975 |
A study of developmental hyperactivity.
Topics: Aggression; Antisocial Personality Disorder; Attention; Behavior Therapy; Child; Child Behavior Diso | 1972 |
Treating problem children with stimulant drugs.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1973 |
What have we learned from psychoactive drug research on hyperactives?
Topics: Amphetamine; Antidepressive Agents; Child; Clinical Trials as Topic; Evaluation Studies as Topic; Hu | 1972 |
The growth of children given stimulant drugs.
Topics: Appetite; Body Height; Body Weight; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Educ | 1973 |
Minimal brain dysfunction in children. Diagnosis and management.
Topics: Abnormalities, Multiple; Affective Symptoms; Age Factors; Amphetamine; Attention; Attention Deficit | 1973 |
Genetic issues in the syndrome of minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Diseases in Twins; Female; Humans; | 1973 |
[The hyperkinetic syndrom in childhood (author's transl)].
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Humans; Hyperkinesis; M | 1974 |
The neurologic learning disability syndrome.
Topics: Anorexia Nervosa; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, C | 1971 |
[Stimulants in the treatment of hyperkinetic behavior disorders].
Topics: Amphetamine; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Humans; Hyperkine | 1971 |
75 trials available for methylphenidate and Hyperactivity, Motor
| Article | Year |
|---|---|
The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Catechol O-Met | 2011 |
Methylphenidate and hyperactivity: effects on teacher behaviors.
Topics: Adult; Behavior; Child; Humans; Hyperkinesis; Interpersonal Relations; Male; Methylphenidate; Teachi | 1980 |
Behavioral and stimulant treatment of hyperactive children: a therapy study with methylphenidate probes in a within-subject design.
Topics: Attention; Behavior Therapy; Child; Dose-Response Relationship, Drug; Female; Humans; Hyperkinesis; | 1980 |
A survey study of the use of electropupillogram in predicting response to psychostimulants.
Topics: Adolescent; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; | 1978 |
The effect of the stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children.
Topics: Adolescent; Child; Clinical Trials as Topic; Dextroamphetamine; Female; Growth Hormone; Homeostasis; | 1977 |
Central nervous system stimulants--their use in the "non-classical" hyperkinetic syndrome: a case-controlled study.
Topics: Appetite; Child; Clinical Trials as Topic; Crying; Dextroamphetamine; Humans; Hyperkinesis; Male; Me | 1977 |
Amitriptyline and methylphenidate treatment of behaviorally disordered children.
Topics: Aggression; Amitriptyline; Attention; Child; Child Behavior Disorders; Clinical Trials as Topic; Hum | 1977 |
The relative efficacy of methylphenidate (ritalin) and behavior-modification techniques in the treatment of a hyperactive child.
Topics: Achievement; Aggression; Attention; Behavior Therapy; Child; Clinical Trials as Topic; Generalizatio | 1977 |
Nutrient intake and stimulant drugs in hyperactive children.
Topics: Ascorbic Acid; Calcium, Dietary; Child; Clinical Trials as Topic; Dextroamphetamine; Diet; Dietary P | 1977 |
The effects of long-term stimulant medication on the growth and body composition of hyperactive children [proceedings].
Topics: Body Composition; Child; Clinical Trials as Topic; Female; Growth; Humans; Hyperkinesis; Male; Methy | 1977 |
Preliminary report on the efficacy of methylphenidate and behavior modification in hyperkinetic children [proceedings].
Topics: Behavior Therapy; Child; Clinical Trials as Topic; Humans; Hyperkinesis; Methylphenidate; Psychiatri | 1977 |
Stimulant drug therapy in hyperactive children: research and clinical implications.
Topics: Adolescent; Behavior Therapy; Child; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; | 1977 |
Hyperkinesis, autonomic nervous system activity and stimulant drug effects.
Topics: Arousal; Attention; Autonomic Nervous System; Child; Child, Preschool; Clinical Trials as Topic; Dou | 1977 |
Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior.
Topics: Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Heart Rate; | 1977 |
Relative effects of drugs and diet on hyperactive behaviors: an experimental study.
Topics: Adolescent; Child; Child Behavior; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; Do | 1978 |
An examination of the double-blind design in drug research with hyperactive children.
Topics: Adolescent; Child; Clinical Trials as Topic; Double-Blind Method; Humans; Hyperkinesis; Methylphenid | 1978 |
Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis.
Topics: Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinical Trials as | 1978 |
The effects of methylphenidate on the mother-child interactions of hyperactive children.
Topics: Child; Child Behavior; Child, Preschool; Clinical Trials as Topic; Cooperative Behavior; Dextroamphe | 1979 |
Double-blind and triple-blind assessments of medication and placebo responses in hyperactive children.
Topics: Child; Clinical Trials as Topic; Double-Blind Method; Humans; Hyperkinesis; Male; Methylphenidate; M | 1979 |
A social ecology of hyperactive boys: medication effects in structured classroom environments.
Topics: Attention; Child; Humans; Hyperkinesis; Male; Methylphenidate; Motor Activity; Schools; Social Behav | 1979 |
Peer interaction in a structured communication task: comparisons of normal and hyperactive boys and of methylphenidate (Ritalin) and placebo effects.
Topics: Affect; Attention; Child; Communication; Double-Blind Method; Humans; Hyperkinesis; Male; Methylphen | 1979 |
Methylphenidate in hyperkinetic children: differences in dose effects on impulsive behavior.
Topics: Adolescent; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperkines | 1979 |
A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hyperkinesis; Male; Methylphenidate; Motor A | 1979 |
Effects of methylphenidate (Ritalin) on selective attention in hyperactive children.
Topics: Attention; Child; Discrimination Learning; Female; Humans; Hyperkinesis; Male; Mental Recall; Methyl | 1979 |
The effects of methylphenidate on various types of activity level and attention in hyperkinetic children.
Topics: Attention; Child; Child, Preschool; Double-Blind Method; Humans; Hyperkinesis; Male; Methylphenidate | 1977 |
Hyperactive children's underuse of learning time: correction by stimulant treatment.
Topics: Adolescent; Attention; Child; Humans; Hyperkinesis; Methylphenidate; Paired-Associate Learning; Plac | 1977 |
Effects of methylphenidate alone and in combination with behavior modification procedures on the behavior and academic performance of hyperactive children.
Topics: Achievement; Behavior Therapy; Child; Double-Blind Method; Humans; Hyperkinesis; Methylphenidate; Pl | 1978 |
The effects of methylphenidate on the soft neurological signs of hyperactive children.
Topics: Child; Child Behavior; Clinical Trials as Topic; Eye Movements; Female; Follow-Up Studies; Humans; H | 1976 |
Effects of Ritalin on underachieving children: a replication.
Topics: Child; Child Behavior; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hyperkinesis; Inte | 1976 |
Haloperidol and methylphenidate in hyperactive children.
Topics: Child; Child, Preschool; Clinical Trials as Topic; Cognition; Dose-Response Relationship, Drug; Drug | 1976 |
Effects of imipramine and methylphenidate on perceptual-motor performance of hyperactive children.
Topics: Adolescent; Child; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hyperkinesis; Imiprami | 1976 |
Cardiovascular responses of hyperactive children to methylphenidate.
Topics: Age Factors; Blood Pressure; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Elec | 1976 |
Predicting the response of hyperkinetic children to stimulant drugs: a review.
Topics: Amphetamine; Amphetamines; Child; Clinical Trials as Topic; Dextroamphetamine; Electroencephalograph | 1976 |
Effect of long-term treatment of hyperactive children with methylphenidate.
Topics: Child; Child Behavior Disorders; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; Electroc | 1975 |
Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy.
Topics: Amitriptyline; Attention; Child; Female; Humans; Hyperkinesis; Male; Methylphenidate | 1976 |
Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results.
Topics: Administration, Oral; Ambulatory Care; Child; Drug Combinations; Drug Evaluation; Female; Humans; Hy | 1976 |
Evoked potentials in hyperkinetic and normal children under certainty and uncertainty: a placebo and methylphenidate study.
Topics: Acoustic Stimulation; Attention; Child; Evoked Potentials; Humans; Hyperkinesis; Male; Methylphenida | 1976 |
Relative efficacy of methylphenidate and behavior modification in hyperkinetic children: an interim report.
Topics: Attention; Behavior Therapy; Child; Child Behavior Disorders; Female; Humans; Hyperkinesis; Male; Me | 1976 |
Hyperactivity in preschoolers and the effect of methylphenidate.
Topics: Child, Preschool; Clinical Trials as Topic; Cognition; Drug Evaluation; Humans; Hyperkinesis; Impuls | 1975 |
One-year follow-up of hyperactive boys treated with imipramine or methylphenidate.
Topics: Administration, Oral; Body Weight; Child Behavior Disorders; Clinical Trials as Topic; Drug Evaluati | 1975 |
Observations on effects of a central stimulant drug (methylphenidate) in children with hyperactive behavior.
Topics: Birth Weight; Body Weight; California; Central Nervous System; Child; Clinical Trials as Topic; Demo | 1975 |
Methylphenidate and haloperidol in children. Effects on attention, memory, and activity.
Topics: Aggression; Attention; Child; Child, Preschool; Clinical Trials as Topic; Cognition; Dose-Response R | 1975 |
Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Clinical Trial | 1975 |
The effect of methylphenidate on sensory perception in varying degrees of hyperkinetic behaviour.
Topics: Adolescent; Age Factors; Auditory Perception; Child; Clinical Trials as Topic; Drug Evaluation; Fema | 1975 |
The effect of methylphenidate on cardiovascular sensory differentiation on the hyperkinetic syndrome.
Topics: Acoustic Stimulation; Arousal; Child; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperkin | 1975 |
Food additives and hyperactivity.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Feeding Behavior; Fo | 1975 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinic | 1975 |
The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action.
Topics: Analysis of Variance; Blood Pressure; Child; Clinical Trials as Topic; Digestion; Female; Haloperido | 1975 |
Effects of combining methylphenidate and a classroom token system in modifying hyperactive behavior.
Topics: Adolescent; Behavior Therapy; Child; Child Behavior Disorders; Child, Institutionalized; Clinical Tr | 1975 |
Blood pressure and pulse changes in hyperactive children treated with imipramine and methylphenidate.
Topics: Adolescent; Blood Pressure; Body Weight; Child; Clinical Trials as Topic; Drug Evaluation; Female; H | 1975 |
A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
Topics: Adolescent; Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, P | 1976 |
Stimulant-related state-dependent learning in hyperactive children.
Topics: Child; Humans; Hyperkinesis; Learning; Memory; Methylphenidate; Retention, Psychology | 1976 |
Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children.
Topics: Child; Circadian Rhythm; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Method; Humans; H | 1989 |
A controlled trial of methylphenidate in black adolescents. Attentional, behavioral, and physiological effects.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Black or African American; Dru | 1988 |
Proceedings: Dose effects of stimulants in hyperkinetic children.
Topics: Central Nervous System Stimulants; Child; Clinical Trials as Topic; Cognition; Dose-Response Relatio | 1974 |
Long-term methylphenidate treatment of hyperkinetic children.
Topics: Child; Clinical Trials as Topic; Follow-Up Studies; Humans; Hyperkinesis; Long-Term Care; Methylphen | 1974 |
Physiological studies of the hyperkinetic child. I.
Topics: Acoustic Stimulation; Arousal; Auditory Perception; Cerebral Cortex; Child; Clinical Trials as Topic | 1972 |
What have we learned from psychoactive drug research on hyperactives?
Topics: Amphetamine; Antidepressive Agents; Child; Clinical Trials as Topic; Evaluation Studies as Topic; Hu | 1972 |
Depression of growth in hyperactive children on stimulant drugs.
Topics: Body Height; Body Weight; Child; Clinical Trials as Topic; Dextroamphetamine; Growth; Humans; Hyperk | 1972 |
The effect of methylphenidate (ritalin) on sustained attention in hyperactive children.
Topics: Adolescent; Attention; Child; Child Behavior; Child, Preschool; Clinical Trials as Topic; Female; Hu | 1972 |
Methylphenidate in the treatment of hyperkinetic children.
Topics: Child; Child Behavior; Clinical Trials as Topic; Drug Evaluation; Humans; Hyperkinesis; Methylphenid | 1974 |
Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children.
Topics: Aggression; Anxiety; Attention; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials a | 1974 |
Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison.
Topics: Attention; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials as Topic; Cognition; D | 1974 |
Hyperactive children. A continuous long-term placebo-controlled follow-up.
Topics: Age Factors; Child; Clinical Trials as Topic; Dextroamphetamine; Drug Evaluation; Follow-Up Studies; | 1974 |
Methylphenidate in children--effect of dosage.
Topics: Analysis of Variance; Child; Child Behavior Disorders; Clinical Trials as Topic; Emotions; Female; H | 1974 |
Platelet serotonin of hyperactive school age boys.
Topics: Blood Platelets; Child; Child Behavior Disorders; Clinical Trials as Topic; Humans; Hyperkinesis; Im | 1974 |
The effect of methylphenidate on sensory perception and integration in hyperactive children.
Topics: Analysis of Variance; Auditory Perception; Child; Clinical Trials as Topic; Female; Humans; Hyperkin | 1974 |
Reduction of hyperactive behavior by conditioning procedures alone and combined with methylphenidate (Ritalin).
Topics: Behavior Therapy; Child; Conditioning, Psychological; Evaluation Studies as Topic; Humans; Hyperkine | 1973 |
Methylphenidate and thioridazine: learning, reaction time, activity, and classroom behavior in disturbed children.
Topics: Achievement; Affective Symptoms; Analysis of Variance; Attention; Child; Clinical Trials as Topic; C | 1970 |
Attention in hyperactive children and the effect of methylphenidate (ritalin).
Topics: Analysis of Variance; Attention; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; | 1971 |
The effect of methylphenidate on behavior of three school children: a pilot investigation.
Topics: Child; Child Behavior Disorders; Clinical Trials as Topic; Humans; Hyperkinesis; Male; Methylphenida | 1971 |
The effect of methylphenidate on attentive behavior and autonomic activity in hyperactive children.
Topics: Adolescent; Attention; Autonomic Nervous System; Child; Child, Preschool; Clinical Trials as Topic; | 1971 |
Alpha rhythms in the hyperkinetic child.
Topics: Cerebral Cortex; Child; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; Electroenceph | 1971 |
Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children.
Topics: Child; Child Behavior Disorders; Chlorpromazine; Dextroamphetamine; Female; Humans; Hyperkinesis; Le | 1971 |
226 other studies available for methylphenidate and Hyperactivity, Motor
| Article | Year |
|---|---|
Haloperidol and methylphenidate alter motor behavior and responses to conditioned fear of Carioca Low-conditioned Freezing rats.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Conditioning, Psy | 2021 |
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopam | 2020 |
Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Female; Hyperkinesis; Imidazoles; Methylphenidate; Mice | 2020 |
Mice with mutations in Trpm1, a gene in the locus of 15q13.3 microdeletion syndrome, display pronounced hyperactivity and decreased anxiety-like behavior.
Topics: Animals; Anxiety; Biogenic Monoamines; Brain Chemistry; Chromosomes, Human, Pair 15; Exploratory Beh | 2021 |
Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Corpus Striatu | 2019 |
[Methylphenidate use in dogs with attention deficit hyperactivity disorder (ADHD). A case report of a Weimaraner bitch].
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Dog Diseases; Dogs; Female; Hyperkines | 2014 |
Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Fever; Hype | 2014 |
[The pills are also effective in the dog].
Topics: Animals; Central Nervous System Stimulants; Dog Diseases; Dogs; Hyperkinesis; Methylphenidate; Treat | 2014 |
Restless Sleep in a Hyperactive Girl: A Paradoxical Adverse Reaction to Methylphenidate.
Topics: Central Nervous System Stimulants; Child; Female; Humans; Hyperkinesis; Methylphenidate; Sleep Wake | 2015 |
Unraveling the nature of hyperactivity in children with attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulan | 2010 |
Mice lacking p35 display hyperactivity and paradoxical response to psychostimulants.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Cyclin-Dependent Kinase 5; Dextroamphet | 2010 |
Intermittent methylphenidate during adolescent development produces locomotor hyperactivity and an enhanced response to cocaine compared to continuous treatment in rats.
Topics: Age Factors; Animals; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Adminis | 2010 |
Impairment of neuropsychological behaviors in ganglioside GM3-knockout mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Emotions; Female; G(M3) Ga | 2011 |
Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Glyc | 2013 |
Differential sensitivity to acute administration of Ritalin, apomorphine, SCH 23390, but not raclopride in mice selectively bred for hyperactive wheel-running behavior.
Topics: Animals; Animals, Outbred Strains; Apomorphine; Benzazepines; Breeding; Disease Models, Animal; Dopa | 2003 |
[CHANGES INDUCED BY SOME PSYCHOPHARMACOLOGICAL AGENTS IN CIRCULATORY AND NEUROPSYCHIC CONDITIONS DUE TO ENVIRONMENTAL HYPER-PRESSURE].
Topics: Acetates; Atmospheric Pressure; Cardiovascular System; Central Nervous System Stimulants; Cerebrovas | 1963 |
European clinical guidelines for hyperkinetic disorder -- first upgrade.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ch | 2004 |
Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive.
Topics: Age Factors; Analysis of Variance; Animals; Attention; Attention Deficit Disorder with Hyperactivity | 2006 |
Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains.
Topics: Adolescent; Age Factors; Aging; Animals; Behavior, Animal; Central Nervous System; Central Nervous S | 2006 |
Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Cell Count; Central Nervous System Stim | 2008 |
A pilot study of the effects of methylphenidate on the vigilance-related EEG in hyperactivity.
Topics: Alpha Rhythm; Attention; Child; Electroencephalography; Evoked Potentials; Humans; Hyperkinesis; Mal | 1980 |
Pharmacokinetics of methylphenidate in man, rat and monkey.
Topics: Adult; Animals; Child; Haplorhini; Humans; Hyperkinesis; Kinetics; Male; Methylphenidate; Rats; Spec | 1983 |
Clinical correlates of methylphenidate blood levels.
Topics: Adult; Aging; Blood Pressure; Blood Specimen Collection; Child; Emotions; Female; Growth Hormone; Hu | 1984 |
Auditory ERP augmentation-reduction and methylphenidate dosage needs in attention and reading disordered children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Dyslexia; Evoked Potentia | 1983 |
Haloperidol-induced hyperactivity in neonatal rats: effect of lithium and stimulants.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Humans; H | 1982 |
Perseveration induced by methylphenidate in children: preliminary findings.
Topics: Attention; Child; Child, Preschool; Double-Blind Method; Female; Humans; Hyperkinesis; Male; Mental | 1982 |
Deleterious effects of drugs used for hyperactivity on patients with Gilles de la Tourette syndrome.
Topics: Child; Haloperidol; Humans; Hyperkinesis; Male; Methylphenidate; Pemoline; Tourette Syndrome | 1980 |
The behavioral mechanism to explain abnormal behavior.
Topics: Behavior; Chlorpromazine; Conditioning, Operant; Dose-Response Relationship, Drug; Extinction, Psych | 1980 |
Hyperkinetic syndrome and Tourette syndrome.
Topics: Adolescent; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate; Pemoline; Tourett | 1982 |
Methylphenidate treatment of hyperactive children: effects on the hypothalamic-pituitary-somatomedin axis.
Topics: Adolescent; Body Height; Body Weight; Child; Female; Growth Hormone; Humans; Hyperkinesis; Hypothala | 1982 |
Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum.
Topics: Adolescent; Child; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hyperkinesis; Kinetics; | 1980 |
Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate [proceedings].
Topics: Adolescent; Body Height; Body Weight; Child; Child Development; Humans; Hyperkinesis; Longitudinal S | 1981 |
Growth hormone and prolactin secretion in adults and hyperactive children: relation to methylphenidate serum levels.
Topics: Adult; Child; Female; Growth Hormone; Humans; Hyperkinesis; Male; Methylphenidate; Prolactin | 1981 |
Hyperkinesis comes of age: what do we know and where should we go?
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Diagnosis, Differ | 1980 |
Imipramine and methylphenidate in hyperactive children.
Topics: Cardiovascular System; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Metho | 1980 |
Methylphenidate and hyperactivity.
Topics: Child; Humans; Hyperkinesis; Methylphenidate | 1980 |
[Hypermotoric syndrome in childhood].
Topics: Attention Deficit Disorder with Hyperactivity; Child; Environment; Female; Humans; Hyperkinesis; Mal | 1980 |
Some thoughts on the social ecology of present day psychopharmacology.
Topics: Attitude of Health Personnel; Child; Child, Preschool; Female; Humans; Hyperkinesis; Male; Methylphe | 1980 |
Methylphenidate, neuroleptics and dyskinesia-dystonia.
Topics: Asthma; Child, Preschool; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyp | 1980 |
[The restless child].
Topics: Child; Humans; Hyperkinesis; Male; Methylphenidate; Prognosis; Psychological Tests | 1980 |
Acceptability of alternative treatments for deviant child behavior.
Topics: Behavior Therapy; Child; Child Behavior Disorders; Child, Preschool; Education of Intellectually Dis | 1980 |
Impulsivity and psychoeducational intervention in hyperactive children.
Topics: Adolescent; Age Factors; Behavior Therapy; Child; Dextroamphetamine; Female; Humans; Hyperkinesis; I | 1980 |
Growth disturbances in hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Growth Disorders; Humans; H | 1980 |
Pharmacological factors of methylphenidate metabolism in behaviorally disordered children.
Topics: Blood Proteins; Child; Humans; Hyperkinesis; Kinetics; Methylphenidate; Protein Binding | 1980 |
Notification of tuberculosis.
Topics: Humans; Hyperkinesis; Methylphenidate; Placebos | 1980 |
Methylphenidate for hyperactivity.
Topics: Child; Humans; Hyperkinesis; Methylphenidate | 1980 |
Multimodality treatment. A two-year evaluation of 61 hyperactive boys.
Topics: Achievement; Attention; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate; Motor | 1980 |
[Hyperkinetic syndrome in childhood].
Topics: Child; Child, Preschool; Humans; Hyperkinesis; Methylphenidate | 1980 |
Treatment of attention-deficit hyperactivity disorder.
Topics: Humans; Hyperkinesis; Methylphenidate; Public Relations | 1993 |
Treatment of attention-deficit hyperactivity disorder.
Topics: Humans; Hyperkinesis; Methylphenidate; Public Relations | 1993 |
Imipramine and amitriptyline in hyperactive children.
Topics: Amitriptyline; Child; Humans; Hyperkinesis; Imipramine; Methylphenidate | 1996 |
Peptide N- and P/Q-type Ca2+ blockers inhibit stimulant-induced hyperactivity in mice.
Topics: Animals; Calcium Channel Blockers; Central Nervous System Stimulants; Hyperkinesis; Injections, Intr | 1998 |
How stimulant drugs may calm hyperactivity.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Carrier Proteins; C | 1999 |
[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
Topics: Adolescent; Adult; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; | 2001 |
One pill makes you smarter: an ethical appraisal of the rise of Ritalin.
Topics: Behavior; Behavior Control; Biomedical Enhancement; Child; Ethics; Goals; Humans; Hyperkinesis; Ment | 1998 |
An analysis of the legal issue surrounding the forced use of Ritalin: protecting a child's right to "just say no.
Topics: Administrative Personnel; Behavior; Behavior Control; Child; Civil Rights; Coercion; Decision Making | 1993 |
Cromolyn DSG effects in hyperkinetic and psychotic children with allergies.
Topics: Adolescent; Adult; Child; Cromolyn Sodium; Dose-Response Relationship, Drug; Drug Evaluation; Humans | 1979 |
A review of psychophysiological research with hyperkinetic children.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Autonomic Nervous System; Blood Pressur | 1978 |
Hyperkinesia and its treatment.
Topics: Amphetamines; Humans; Hyperkinesis; Methylphenidate; Pemoline | 1978 |
Follow-up survey results of medication used to treat hyperactive school children.
Topics: Child; Dextroamphetamine; Drug Prescriptions; Follow-Up Studies; Humans; Hyperkinesis; Income; Maryl | 1979 |
The effect of central nervous system stimulants on Tourette syndrome.
Topics: Child, Preschool; Humans; Hyperkinesis; Male; Methylphenidate; Tourette Syndrome | 1977 |
Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy.
Topics: Adult; Child; Dextroamphetamine; Haloperidol; Humans; Hyperkinesis; Male; Methylphenidate; Pedigree; | 1977 |
Hyperactive children: problems, issues and approaches.
Topics: Amphetamines; Behavior Therapy; Child; Child Behavior Disorders; Counseling; Dextroamphetamine; Fami | 1978 |
Methylphenidate-induced Tourette syndrome: case report.
Topics: Child; Dose-Response Relationship, Drug; Humans; Hyperkinesis; Male; Methylphenidate; Tourette Syndr | 1979 |
Imipramine and children: a review and some speculations about the mechanism of drug action.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Depression; Dopamine; Enuresis; Epilepsy, Absence; | 1977 |
Family practice grand rounds. Hyperactivity: a symptom, not a disease entity.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Epilepsy, Absence; | 1977 |
Growth of hyperactive children treated with methylphenidate.
Topics: Body Height; Body Weight; Child; Child Development; Drug Administration Schedule; Humans; Hyperkines | 1979 |
A four-fold model for subgrouping the hyperkinetic/MBD syndrome.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Humans; Hyperkinesis; | 1979 |
Auditory attention in hyperactive children: effects of stimulant medication on dichotic listening performance.
Topics: Acoustic Stimulation; Adolescent; Attention; Auditory Perception; Child; Dominance, Cerebral; Female | 1979 |
Clinical experience with methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cerebral Palsy; Child; Child, Preschool; | 1979 |
Nonproprietary name and trademarks of drug.
Topics: Adolescent; Child; Diseases in Twins; Female; Glucagon; Growth Hormone; Humans; Hyperkinesis; Male; | 1979 |
Drug treatment for hyperactivity: controversies, alternatives, and guidelines.
Topics: Amphetamines; Behavior Therapy; Child; Drug Evaluation; Humans; Hyperkinesis; Insurance, Liability; | 1979 |
Nocturnal levels of growth hormone in hyperactive children of small stature.
Topics: Body Height; Child; Growth Hormone; Humans; Hyperkinesis; Male; Methylphenidate; Sleep Stages | 1979 |
Muller-Lyer illusion in hyperactive boys.
Topics: Age Factors; Child; Child Development; Humans; Hyperkinesis; Illusions; Impulsive Behavior; Male; Me | 1979 |
The effects of stimulant medication on the growth of hyperkinetic children.
Topics: Adolescent; Body Height; Body Weight; Child Behavior Disorders; Dextroamphetamine; Growth; Growth Di | 1979 |
Methylphenidate (ritalin)
Topics: Child; Humans; Hyperkinesis; Methylphenidate; South Africa; Surveys and Questionnaires | 1979 |
Abuse of prescribed stimulant medication by a 13-year-old hyperactive boy.
Topics: Adolescent; Humans; Hyperkinesis; Male; Methylphenidate; Substance-Related Disorders | 1979 |
Multimodality treatment. A one-year follow-up of 84 hyperactive boys.
Topics: Achievement; Antisocial Personality Disorder; Child; Follow-Up Studies; Humans; Hyperkinesis; Intell | 1979 |
Behavior modification therapy in hyperactive children. Research and clinical implications.
Topics: Adolescent; Behavior Therapy; Child; Child, Preschool; Evaluation Studies as Topic; Female; Humans; | 1979 |
Comparing psychological and pharmacological treatments for hyperkinetic boys and their classmates.
Topics: Attention; Behavior Therapy; Child; Humans; Hyperkinesis; Male; Methylphenidate; Motor Activity; Pee | 1979 |
Stimulant drugs and activity level in hyperactive children.
Topics: Attention; Child; Child, Preschool; Exploratory Behavior; Humans; Hyperkinesis; Male; Methylphenidat | 1979 |
A review of psychopharmacological and behavioral approaches to the treatment of hyperactive children.
Topics: Aggression; Attention; Behavior Therapy; Child; Humans; Hyperkinesis; Methylphenidate | 1979 |
Effects of clinical dosage levels of methylphenidate on two-flash thresholds and perceptual motor performance in hyperactive children.
Topics: Attention; Auditory Perception; Child; Discrimination Learning; Humans; Hyperkinesis; Male; Methylph | 1979 |
A comparison of analysis of covariance and the theta technique as applied to illustrative psychopharmacological data.
Topics: Analysis of Variance; Child; Drug Therapy, Combination; Humans; Hyperkinesis; Methylphenidate; Stati | 1979 |
Effects of methylphenidate on hyperactive children's ability to sustain attention.
Topics: Attention; Child; Female; Humans; Hyperkinesis; Male; Methylphenidate; Psychiatric Status Rating Sca | 1979 |
The policy culture of drugs: Ritalin, methadone, and the control of deviant behavior.
Topics: Child; Heroin Dependence; Humans; Hyperkinesis; Methadone; Methylphenidate; Politics; Public Policy; | 1979 |
Long-term use and discontinuation of methylphenidate with hyperactive children.
Topics: Achievement; Behavior; Child; Female; Humans; Hyperkinesis; Intelligence Tests; Male; Methylphenidat | 1979 |
Operant conditioning of EEG rhythms and ritalin in the treatment of hyperkinesis.
Topics: Biofeedback, Psychology; Child; Conditioning, Operant; Electroencephalography; Evaluation Studies as | 1979 |
Pharmacokinetics of methylphenidate in hyperkinetic children.
Topics: Biotransformation; Blood Proteins; Child; Half-Life; Humans; Hyperkinesis; Kinetics; Methylphenidate | 1979 |
Methylphenidate (ritalin)
Topics: Child; Child, Preschool; Humans; Hyperkinesis; Methylphenidate | 1978 |
Methylphenidate-induced chorea: case report and pharmacologic implications.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Child; Child, Preschool; Chorea; Dopa | 1978 |
Changes in the electroencephalogram accompanying the use of stimulant drugs (methylphenidate and dextroamphetamine) in hyperactive children.
Topics: Attention; Child; Child, Preschool; Computers; Dextroamphetamine; Electroencephalography; Evoked Pot | 1977 |
Stimulant effects on cooperation and social interaction between hyperactive children and their mothers.
Topics: Child; Cooperative Behavior; Double-Blind Method; Female; Humans; Hyperkinesis; Methylphenidate; Mot | 1978 |
Methylphenidate and growth retardation.
Topics: Child; Growth Disorders; Growth Hormone; Humans; Hyperkinesis; Male; Methylphenidate | 1978 |
Behavior therapy and withdrawal of stimulant medication in hyperactive children.
Topics: Behavior Therapy; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Parents; Psychiat | 1978 |
Effects of a stimulant drug on extraversion level in hyperactive children.
Topics: Adolescent; Attention; Auditory Perception; Child; Extraversion, Psychological; Humans; Hyperkinesis | 1978 |
[Treatment of a child with major psychomotor instability by methylphenidate: effects on his psychotherapy].
Topics: Child; Humans; Hyperkinesis; Male; Methylphenidate; Psychotherapy | 1978 |
The effects of frontal EMG biofeedback and progressive relaxation upon hyperactivity and its behavioral concomitants.
Topics: Adolescent; Biofeedback, Psychology; Body Temperature; Child; Electromyography; Facial Muscles; Fema | 1978 |
Stimulant drug therapy in control of on-task behavior: a case study.
Topics: Achievement; Child; Child Behavior; Drug Evaluation; Humans; Hyperkinesis; Male; Methylphenidate | 1978 |
The behavioral symptoms of hyperkinetic children who successfully responded to stimulant drug treatment.
Topics: Attention; Child; Child Behavior Disorders; Child, Preschool; Humans; Hyperkinesis; Male; Methylphen | 1978 |
The effects of caffeine and methylphenidate on hyperactive children.
Topics: Caffeine; Child; Double-Blind Method; Drug Evaluation; Female; Humans; Hyperkinesis; Male; Methylphe | 1978 |
Physiological basis of hyperkinesis treated with methylphenidate.
Topics: Arousal; Auditory Cortex; Child; Child Behavior; Electroencephalography; Electromyography; Evoked Po | 1978 |
Hyperkinetic/aggressive boys in treatment: predictors of clinical response to methylphenidate.
Topics: Age Factors; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Fem | 1978 |
The effects of methylphenidate on the mother-child interactions of hyperactive identical twins.
Topics: Adult; Attention; Child Behavior; Child, Preschool; Cooperative Behavior; Diseases in Twins; Female; | 1978 |
Growth of hyperactive children treated with methylphenidate.
Topics: Age Factors; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Child; Child, | 1978 |
Effects of methylphenidate on hyperactive children's evoked responses during passive and active attention.
Topics: Attention; Child; Electroencephalography; Electrooculography; Evoked Potentials; Female; Humans; Hyp | 1979 |
Judgments of educators and child-care personnel about appropriate treatment for mentally retarded or normal, overactive or withdrawn, boys.
Topics: Allied Health Personnel; Attitude of Health Personnel; Behavior Therapy; Child; Child Behavior Disor | 1976 |
Effect of methylphenidate on sleep stages and ultradian rhythms in hyperactive children.
Topics: Child; Delta Rhythm; Electroencephalography; Humans; Hyperkinesis; Male; Methylphenidate; Sleep Stag | 1977 |
Comparing treatment tactics with a hyperactive preschool child: stimulant medication and programmed teacher intervention.
Topics: Achievement; Attention; Behavior Therapy; Child, Preschool; Cooperative Behavior; Humans; Hyperkines | 1977 |
The hyperactive child syndrome.
Topics: Child; Dextroamphetamine; Diphenhydramine; Humans; Hyperkinesis; Imipramine; Methylphenidate; Pemoli | 1977 |
Sleep disturbance in hyperkinetic children.
Topics: Child; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; Methylphenidate; Sle | 1977 |
Methylphenidate (ritalin) and other drugs for treatment of hyperactive children.
Topics: Child; Deanol; Dextroamphetamine; Drug Interactions; Humans; Hyperkinesis; Imipramine; Methylphenida | 1977 |
Hyperactivity among white middle-class children. Psychogenic and other causes.
Topics: Adolescent; Affective Symptoms; Aggression; Amphetamines; Anxiety; Attention Deficit Disorder with H | 1977 |
Mentally retarded, hyperkinetic and psychotic.
Topics: Adult; Female; Humans; Hyperkinesis; Indoles; Intellectual Disability; Methylphenidate; Molindone; P | 1977 |
Childhood depression: an explanation of a behavior disorder of children.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Child; Child Behavior Disorders; Depression; Dex | 1977 |
Agreement of mothers' and teachers' hyperactivity ratings with scores on drug-sensitive psychological tests.
Topics: Attention; Child; Female; Humans; Hyperkinesis; Male; Methylphenidate; Parents; Psychological Tests; | 1977 |
The medication clinic in the spectrum of children's services.
Topics: Child; Child Health Services; Child, Preschool; Dextroamphetamine; Female; Humans; Hyperkinesis; Mal | 1977 |
Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dextroamphetamin | 1976 |
Practical use of psychotropic drugs in children.
Topics: Adolescent; Child; Child Behavior Disorders; Enuresis; Humans; Hyperkinesis; Imipramine; Methylpheni | 1976 |
Averaged evoked potential predictors of clinical improvement in hyperactive children treated with methylphenidate: an initial study and replication.
Topics: Attention; Child; Evoked Potentials; Female; Humans; Hyperkinesis; Male; Methylphenidate; Placebos; | 1976 |
The role of whole blood serotonin levels in monitoring vitamin B6 and drug therapy in hyperactive children.
Topics: Adolescent; Behavior; Child; Humans; Hyperkinesis; Methylphenidate; Pyridoxine; Serotonin | 1976 |
Letter: Methylphenidate-induced tics.
Topics: Humans; Hyperkinesis; Methylphenidate; Tic Disorders | 1976 |
View of china questioned.
Topics: Child; Humans; Hyperkinesis; Methylphenidate | 1976 |
The hyperactive child.
Topics: Achievement; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cr | 1976 |
The hyperactive young child with normal intelligence.
Topics: Child; Child Behavior Disorders; Child Rearing; Child, Preschool; Crying; Feeding Behavior; Female; | 1976 |
Comprehensive management of the hyperkinetic child.
Topics: Adolescent; Amphetamines; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; | 1976 |
The hyperkinetic child syndrome: the need for reassessment.
Topics: Amygdala; Behavior Therapy; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Social Adjustm | 1976 |
The reliability and diagnostic validity of the physical and neurological examination for soft signs (PANESS).
Topics: Brain Damage, Chronic; Child; Child, Preschool; Evaluation Studies as Topic; Haloperidol; Humans; Hy | 1976 |
[The hyperactive child].
Topics: Child; Counseling; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1975 |
Is there a relationship between allergy and learning disabilities?
Topics: Child; Humans; Hyperkinesis; Hypersensitivity; Learning Disabilities; Male; Methylphenidate; School | 1976 |
Effect of methylphenidate on cardiorespiratory responses in hyperactive children.
Topics: Child; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hyperkinesis; Male; Methylpheni | 1976 |
Growth rebound after termination of stimulant drugs.
Topics: Adolescent; Body Height; Body Weight; Child; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; | 1975 |
Editorial: The hyperactive child.
Topics: Age Factors; Child; Child Behavior Disorders; Child, Preschool; Chlorpromazine; Dextroamphetamine; H | 1975 |
Letter: The hyperactive child.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Hyperkinesis; Methylphenidate | 1975 |
Hyperkinesis and maternal smoking.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Hyperkinesis; Male; Methylphenidate; Pre | 1975 |
Letter: Growth of hyperactive children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Growth; Humans; Hyperkinesis; Methylphenidate; | 1975 |
Medication for hyperkinetic children.
Topics: Administration, Oral; Attention; Child; Dextroamphetamine; Humans; Hyperkinesis; Intelligence; Methy | 1975 |
A reproducible gas chromatographic mass spectrometric assay for low levels of methylphenidate and ritalinic acid in blood and urine.
Topics: Adult; Child; Chromatography, Gas; Female; Humans; Hyperkinesis; Male; Mass Spectrometry; Methylphen | 1975 |
Hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Reactive Disorders; Dextroamphetamine; D | 1975 |
Dyslexia.
Topics: Attention; Child; Dextroamphetamine; Dyslexia; Humans; Hyperkinesis; Mental Processes; Mental Recall | 1975 |
The influences of methylphenidate on heart rate and behavioral measures of attention in hyperactive children.
Topics: Attention; Child; Child Behavior; Female; Heart Rate; Humans; Hyperkinesis; Male; Methylphenidate; R | 1975 |
Stimulant drug treatment of hyperactive adolescents.
Topics: Adolescent; Age Factors; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Evaluation | 1975 |
The hyperkinetic child.
Topics: Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; School Nursing | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Anta | 1975 |
Using cerebral stimulants to treat minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Child; Humans; Hyperkin | 1975 |
The paradoxical effects of CNS stimulants on hyperkinetic behavior.
Topics: Adolescent; Animals; Child; Child, Preschool; Female; Humans; Hyperkinesis; Male; Methylphenidate; M | 1975 |
A behavioral-educational alternative to drug control of hyperactive children.
Topics: Achievement; Behavior Therapy; Child; Female; Humans; Hyperkinesis; Learning Disabilities; Male; Met | 1975 |
The learning-disabled or hyperactive child: diagnosis and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; H | 1975 |
Stimulant drugs for hyperactivity: some additional disturbing questions.
Topics: Attention; Child; Civil Rights; Dextroamphetamine; Drug Evaluation; Family Therapy; Humans; Hyperkin | 1976 |
Methylphenidate: a review.
Topics: Attention Deficit Disorder with Hyperactivity; Humans; Hyperkinesis; Methylphenidate; Substance-Rela | 1976 |
Sequential withdrawal of stimulant drugs and use of behavior therapy with two hyperactive boys.
Topics: Amphetamine; Behavior Therapy; Child; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1976 |
Current medical practice and hyperactive children.
Topics: Attitude of Health Personnel; Child; Child Behavior; Child Psychiatry; Counseling; Dextroamphetamine | 1976 |
Letter: The hyperkinetic child.
Topics: Child; Dextroamphetamine; Ethics, Medical; Humans; Hyperkinesis; Methylphenidate | 1976 |
Letter: Behavioral treatment of hyperkinesis.
Topics: Behavior Therapy; Child; Humans; Hyperkinesis; Male; Methylphenidate | 1976 |
Effect of a media blitz and a threatened lawsuit on stimulant treatment.
Topics: Baltimore; Child; Drug Utilization; Humans; Hyperkinesis; Maryland; Methylphenidate; Public Relation | 1992 |
The paradox effect of psychostimulants in the treatment of the child hyperkinetic syndrome.
Topics: Amphetamines; Central Nervous System Stimulants; Child; Electroencephalography; Female; Humans; Hype | 1990 |
Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children.
Topics: Attention Deficit Disorder with Hyperactivity; Body Constitution; Child; Drug Tolerance; Female; Hum | 1989 |
Psychopharmacologic facilitation of psychosocial therapy of violence and hyperkinesis.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Behavior, Animal; | 1988 |
Effects of methylphenidate on achievement in hyperactive children with reading disorders.
Topics: Achievement; Adolescent; Child; Humans; Hyperkinesis; Methylphenidate; Reading | 1988 |
Effects of methylphenidate dosage in hyperactive reading-disabled children: I. Behavior and cognitive performance effects.
Topics: Adolescent; Child; Cognition; Dose-Response Relationship, Drug; Dyslexia; Humans; Hyperkinesis; Meth | 1988 |
Hyperactivity and methylphenidate.
Topics: Child; Humans; Hyperkinesis; Methylphenidate | 1987 |
The role of methylphenidate and dextroamphetamine in hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Developmental Disabilities; Dextroamphetamine; | 1971 |
Methylphenidate in akathisia.
Topics: Adult; Humans; Hyperkinesis; Male; Methylphenidate; Schizophrenia; Tranquilizing Agents | 1972 |
The adolescent with a learning problem. The need for insight.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Community Mental Health Serv | 1973 |
School problems: diagnosis and treatment.
Topics: Agnosia; Amphetamine; Anxiety; Child; Child, Preschool; Cognition Disorders; Developmental Disabilit | 1973 |
Letter: Benztropine in childhood hyperkinesis.
Topics: Adolescent; Benztropine; Child; Chlorpromazine; Humans; Hyperkinesis; Male; Methylphenidate; Tropane | 1973 |
Protection by catatoxic steroids against the paralysis caused by combined treatment with thyroxine and methylphenidate.
Topics: Androstenols; Animals; Drug Synergism; Estradiol; Ethylestrenol; Female; Humans; Hydroxysteroids; Hy | 1972 |
Drug treatment of hyperactivity in children.
Topics: Age Factors; Child; Dextroamphetamine; Electroencephalography; Humans; Hyperkinesis; Imipramine; Met | 1973 |
Multimodality treatment of the hyperkinetic child.
Topics: Antidepressive Agents; Behavior Therapy; Counseling; Curriculum; Dextroamphetamine; Family Therapy; | 1974 |
Effects of methylphenidate on hyperactive children's sleep.
Topics: Adolescent; Analysis of Variance; Child; Electroencephalography; Humans; Hyperkinesis; Male; Methylp | 1974 |
Drugs in management of hyperkinetic and perceptually handicapped children.
Topics: Anticonvulsants; Central Nervous System Stimulants; Child; Child, Preschool; Chlordiazepoxide; Chlor | 1968 |
Hyperkineticism in children.
Topics: Amphetamine; Anticonvulsants; Child; Child Behavior Disorders; Humans; Hyperkinesis; Methylphenidate | 1970 |
Type and prevalence of medication used in the treatment of hyperactive children.
Topics: Child; Child Behavior Disorders; Chlorpromazine; Dextroamphetamine; Diphenhydramine; Education, Spec | 1974 |
Proceedings: The relationship between behavioral and psychological test changes in hyperkinetic children.
Topics: Behavior; Child; Humans; Hyperkinesis; Methylphenidate; Psychological Tests; Thioridazine | 1974 |
Proceedings: CNS function and response to methylphenidate in hyperactive children.
Topics: Arousal; Central Nervous System; Child; Electroencephalography; Evoked Potentials; Galvanic Skin Res | 1974 |
Pathophysiology of the hyperactive child syndrome.
Topics: Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Auditory Perception; Brain; Child; | 1974 |
Four types of hyperkinesis.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Child Abuse; Child Behavior | 1974 |
Letter: convulsions and ritalin?
Topics: Child; Humans; Hyperkinesis; Male; Methylphenidate; Seizures | 1974 |
Ritalin for school children: the teachers' perspective.
Topics: Attitude; Child; Humans; Hyperkinesis; Methylphenidate; School Health Services; Teaching | 1973 |
Symposium: behavior modification by drugs. 3. The clinical use of stimulant drugs in children.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Feeding and Eat | 1972 |
Gilles de la Tourette's syndrome following methylphenidate administration.
Topics: Age Factors; Child; Dopamine; Haloperidol; Humans; Hyperkinesis; Male; Methylphenidate; Neurologic M | 1974 |
Amphetamine-type drugs for hyperactive children.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Body Weight; Brain; Child; Dextroamphetamin | 1972 |
Inhibitory functions of attention in reducing hyperactive behavior.
Topics: Attention; Behavior Therapy; Brain; Child; Child, Preschool; Conditioning, Operant; Education of Int | 1972 |
Modification of hyperkinetic behavior by nortriptyline.
Topics: Adolescent; Child; Child, Preschool; Humans; Hyperkinesis; Leukocyte Count; Methylphenidate; Nortrip | 1973 |
Hyperactive children.
Topics: Adolescent; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Humans; Hyperkines | 1973 |
Reaction time and effect of Ritalin on children with learning problems.
Topics: Attention; Child; Discrimination, Psychological; Dyslexia; Female; Form Perception; Humans; Hyperkin | 1973 |
Hyperactive children.
Topics: Adolescent; Butyrophenones; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate | 1973 |
Oral medications for minimal brain dysfunction in children.
Topics: Administration, Oral; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Child Behav | 1973 |
Hyperactive children.
Topics: Brain; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Substance-Related Disorders | 1973 |
Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children.
Topics: Analysis of Variance; Body Height; Body Weight; Child; Dextroamphetamine; Growth Disorders; Humans; | 1973 |
Caffeine as a substitute for Schedule II stimulants in hyperkinetic children.
Topics: Caffeine; Child; Humans; Hyperkinesis; Male; Methylphenidate; Stimulation, Chemical | 1973 |
Learning disabilities in childhood.
Topics: Child; Child, Preschool; Electroencephalography; Female; Humans; Hyperkinesis; Learning Disabilities | 1973 |
Side effects of methylphenidate.
Topics: Brain Damage, Chronic; Child; Child Behavior Disorders; Delusions; Dextroamphetamine; Evaluation Stu | 1973 |
The hyperactive child syndrome.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; C | 1973 |
The making of a myth.
Topics: Age Factors; Child; Dextroamphetamine; Humans; Hyperkinesis; Methylphenidate; Sulfates | 1973 |
The hyperactive child.
Topics: Age Factors; Amphetamine; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Di | 1973 |
[The minimal brain dysfunction syndrome].
Topics: Affective Symptoms; Amphetamine; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Chi | 1973 |
The hyperkinetic syndrome.
Topics: Birth Order; Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Female; Humans; H | 1973 |
Response to methylphenidate in low socioeconomic hyperactive children.
Topics: Age Factors; Child; Child Behavior Disorders; Child, Preschool; Cultural Deprivation; Drug Evaluatio | 1974 |
Minor physical anomalies and plasma dopamine-beta-hydroxylase activity in hyperactive boys.
Topics: Abnormalities, Multiple; Child; Dopamine beta-Hydroxylase; Female; Humans; Hyperkinesis; Imipramine; | 1974 |
Letter: Hereditary factors in hyperkinesis.
Topics: Family; Genetic Diseases, Inborn; Humans; Hyperkinesis; Methylphenidate; Psychoses, Substance-Induce | 1974 |
Gas-liquid chromatographic procedure for measurement of methylphenidate hydrochloride and its metabolite, ritalinic acid, in urine.
Topics: Child; Chromatography, Gas; Evaluation Studies as Topic; Humans; Hyperkinesis; Methods; Methylphenid | 1974 |
Methylphenidate and the activity of hyperactives in the informal setting.
Topics: Attention; Child; Child Behavior; Dose-Response Relationship, Drug; Humans; Hyperkinesis; Methylphen | 1974 |
Minimal brain dysfunctions in children.
Topics: Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Comm | 1974 |
Electrodermal activity in hyperactive boys who are methylphenidate responders.
Topics: Child; Galvanic Skin Response; Humans; Hyperkinesis; Male; Methylphenidate | 1974 |
Lead-induced behavioral dysfunction: an animal model of hyperactivity.
Topics: Amphetamine; Animals; Chloral Hydrate; Dextroamphetamine; Disease Models, Animal; Female; Humans; Hy | 1974 |
Hyperactivity: a lead-induced behavior disorder.
Topics: Amphetamine; Animals; Animals, Newborn; Chloral Hydrate; Diet; Dose-Response Relationship, Drug; Fem | 1974 |
[Psychostimulant treatment of "hyperkinetic" children].
Topics: Amphetamine; Child; Humans; Hyperkinesis; Methylphenidate | 1972 |
Recognizing minimal cerebral dysfunction in the infant and toddler. Some clinical clues and thoughts on management.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child, Preschool; Humans; Hype | 1972 |
Allergic reaction to methylphenidate.
Topics: Child, Preschool; Drug Hypersensitivity; Female; Humans; Hyperkinesis; Methylphenidate | 1972 |
Dissociation of learning on stimulant-drug therapy.
Topics: Amphetamine; Animals; Antidepressive Agents; Child; Dextroamphetamine; Humans; Hyperkinesis; Learnin | 1972 |
Mood-altering drugs and hyperkinetic children.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behavior Disorder | 1972 |
Hyperactivity in children: types, diagosis, drug therapy, approaches to management.
Topics: Amphetamine; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chroni | 1972 |
Electrodermal correlates of hyperactivity in children.
Topics: Arousal; Child; Child Behavior Disorders; Dextroamphetamine; Galvanic Skin Response; Humans; Hyperki | 1971 |
Minimal brain dysfunction and methylphenidate.
Topics: Advertising; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Brain Diseases; C | 1971 |
Mood-altering drugs.
Topics: Amphetamine; Child; Child Behavior; Female; Humans; Hyperkinesis; Male; Methylphenidate; School Heal | 1971 |
Methylphenidate and minimal brain dysfunction.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Child; Child Behav | 1971 |
Amphetamines in hyperkinetic children.
Topics: Amphetamine; Child; Humans; Hyperkinesis; Methylphenidate; Norepinephrine | 1971 |
Methylphenidate hallucinosis.
Topics: Administration, Oral; Adolescent; Age Factors; Alopecia; Catatonia; Child; Chloral Hydrate; Chlorpro | 1971 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
Photic responses in hyperkinesis of childhood.
Topics: Adult; Brain; Child; Child, Preschool; Dextroamphetamine; Electroencephalography; Humans; Hyperkines | 1971 |
Methylphenidate and the hyperkinetic state.
Topics: Ataxia; Child; Drug Synergism; Feeding and Eating Disorders; Humans; Hyperkinesis; Hypertension; Met | 1971 |
Treatment of hyperactivity in children.
Topics: Child; Chlorpromazine; Dextroamphetamine; Female; Humans; Hyperkinesis; Male; Methylphenidate; Thior | 1970 |
An additional observation on methylphenidate in hyperactive children.
Topics: Child; Child Behavior Disorders; Female; Humans; Hyperkinesis; Male; Methylphenidate | 1971 |
Pediatric practice: whose mood are we altering?
Topics: Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; Male; Methylphenidate | 1971 |
Learning disorders, hyperkinesis, and the use of drugs in children.
Topics: Amphetamine; Child; Humans; Hyperkinesis; Learning Disabilities; Methylphenidate; Psychological Test | 1971 |